Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. Topical / intralesional corticosteroids and topical or contact immunotherapy are commonly prescribed. Two JAK inhibitors—Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Litfulo (ritlecitinib)—are approved for severe AA. As the treatment landscape continues to evolve, this report offers insight into prescribing trends to help new players understand current treatment practices in AA and to define the market niche for emerging products.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key drugs: Contact allergens, corticosteroids, cyclosporine A, finasteride, Litfulo, Jakafi, methotrexate, Olumiant, pimecrolimus, retinoids, tacrolimus (topical), Xeljanz
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses